

IGFBP3 Antibody (S183) Blocking Peptide

Synthetic peptide Catalog # BP7641d

Specification

IGFBP3 Antibody (S183) Blocking Peptide - Product Information

Primary Accession P17936

IGFBP3 Antibody (S183) Blocking Peptide - Additional Information

Gene ID 3486

Other Names

Insulin-like growth factor-binding protein 3, IBP-3, IGF-binding protein 3, IGFBP-3, IGFBP3, IBP3

Target/Specificity

The synthetic peptide sequence used to generate the antibody <a >AP7641d was selected from the S183 region of human IGFBP3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

IGFBP3 Antibody (S183) Blocking Peptide - Protein Information

Name IGFBP3


Synonyms IBP3

IGFBP3 Antibody (S183) Blocking Peptide - Background

IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family with an IGFBP domain and a thyroglobulin type-I domain. This protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.

IGFBP3 Antibody (S183) Blocking Peptide - References

Muzumdar,R.H., Diabetes 55 (10), 2788-2796 (2006)Novosyadlyy,R., Growth Horm. IGF Res. 15 (5), 313-323 (2005)





Function

IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R.

Cellular Location Secreted.

Tissue LocationExpressed by most tissues. Present in plasma.

IGFBP3 Antibody (S183) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides